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Introduction
The mediastinum may be the primary localization of va-
rious tumours: thymoma, thymic carcinoma, benign and
malignant soft tissue tumours [1] and germinal tumours
with the most frequent, i.e. seminoma. Nodular sclerosis
Hodgkin lymphoma commonly presents in the mediasti-
num as well as some 15-25 % of non-Hodgkin lymphomas
[2-4]. Precursor T-lymphoblastic lymphoma is the most
frequent, but sporadically one may encounter anaplastic
(CD30-positive) large cell lymphoma [5]. Tumours from
other organs may metastasize to the mediastinum, among
them squamous or small cell anaplastic or undifferentia-
ted pulmonary carcinoma, melanoma, renal clear cell car-
cinoma and others [1].
Primary mediastinal large B-cell lymphoma (PMBL)
has been described fairly recently. Hodgkin lymphoma
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I n t r o d u c t i o n. Mediastinal large B-cell lymphoma (PMBL) is a rare and not easily recognized entity. Histopathological dia-
gnosis is difficult without immunohistochemical studies, due to high cells pleomorphism.
A i m. Evaluation of sections from 51 lymphomas, selection of the panel of antibodies useful in differential diagnosis and at-
tempt at determination of clinical and morphological prognostic factors.
M a t e r i a l a n d m e t h o d s. 51 cases of PMBL diagnosed and treated at the Institute of Oncology in Warsaw. Clinical symp-
toms and varied histopathological appearences with immunohistochemical studies were presented. Statistic analysis of selec-
ted prognostic parameters was performed.
Re s u l t s. Morphologically the lymphoma resembled several other tumours with mediastinal localization and CD20 staining
was decisive for correct diagnosis. Tumour size had a statistically significant effect on overall survival. Among other analyzed
parameters only a few showed a tendency for correlation with survival.
C o n c l u s i o n s. PMBL is a subtype of DLBCL with distinct clinical presentation and histopathological features requiring
differential diagnosis with other mediastinal tumours.
Pierwotny ch∏oniak Êródpiersia z du˝ych komórek B.
Ch∏oniak odmienny od innych ch∏oniaków z du˝ych komórek B
W s t ´ p. Pierwotny ch∏oniak Êródpiersia z du˝ych komórek B jest rzadkà jednostkà, histopatologicznie trudnà do rozpozna-
nia bez badaƒ immunohistochemicznych ze wzgl´du na znaczny pleomorfizm utkania.
M a t e r i a ∏ i m e t o d y. Analiza dotyczy∏a 51 chorych z PMBL. Dane kliniczne zebrano z historii chorób. Oceniono morfo-
logicznie i immunohistochemicznie wycinki z 51 guzów Êródpiersia oraz przeprowadzono analiz´ statystycznà wp∏ywu wybra-
nych parametrów klinicznych i histopatologicznych na prze˝ycie chorych.
W y n i k i. Ze wzgl´du na znaczny pleomorfizm komórek wyodr´bniono 5 podtypów utkania. Ze wzgl´du na podobieƒstwo do
innych nowotworów w tej lokalizacji niezb´dne jest wykonanie barwienia immunohistochemicznego z CD 20. U 21 pacjen-
tów uzyskano CR z czasami prze˝ycia ca∏kowitego od 36 do 99 miesi´cy. ˚yje 24, wÊród nich 3 z przetrwa∏à chorobà. Pozo-
sta∏ych 26 zmar∏o pomimo stosowanego leczenia, z utrzymujàcym si´ guzem i progresjà.
W n i o s k i. PMBL to ch∏oniak morfologicznie bardzo zró˝nicowany. Dla prawid∏owego rozpoznania konieczne jest immuno-
histochemiczne wykazanie ekspresji CD 20. Analiza statystyczna wykaza∏a, ˝e wielkoÊç guza ma istotny wp∏yw na ca∏kowite
prze˝ycie. Inne badane parametry wykaza∏y jedynie tendencj´ do krótszych prze˝yç.
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was the first to be recognized among lymphoid mediasti-
nal tumours. Development of immunocytochemical me-
thods resulted in rapid progress in diagnosis and classifi-
cation of lymphomas [6]. In the late 1970ies T-lymphobla-
stic lymphoma presenting in the mediastinum had been
morphologically and immunologically defined [7-9]. In
the early 1980ies several authors noted non-Hodgkin,
non-lymphoblastic, mediastinal large cell lymphomas as-
sociated with characteristic clinical symptoms [10-13].
The disease mostly affected young women in the third or
fourth decade of life and manifested as anterior mediasti-
nal tumour, frequently with the superior vena cava syn-
drome, generally without involvement of other localiza-
tions. The lymphoma was finally defined as B-cell type [5,
14, 15]. Heterogeneity of these mediastinal tumours was
observed and authors warned against diagnosing them
merely on morphological grounds [1, 3, 10, 14, 16]. Very
often it was impossible to classify mediastinal large cell
lymphomas according to any of the existing classifica-
tions of malignant lymphomas [6, 17]. Lamarre et al.
[16] introduced the term „primary mediastinal large B-
-cell lymphoma”. Their study of 29 cases of PMBL inclu-
ded 18 women and 11 men with median age of 32 years.
The patients presented with the superior vena cava syn-
drome and had localized disease (Ann Arbor stage I or
II) at diagnosis. General symptoms were present in abo-
ut 1/3 of the cases. Morphologically, the tumour cells di-
splayed great pleomorphism. The diagnosis of B-cell
lymphoma was made owing to positive result of staining
with anti-CD 20 antibody and lack of reactivity with anti-
-pan T antibody. Similary to Jacobson [18], prognosis
better than previously reported was observed, due to in-
troduction of aggressive chemotherapy combined with
radiotherapy.
Primary mediastinal large B-cell lymphoma (PMBL)
with a characteristic clinical presentation had been de-
fined as a histoclinical entity acc. to the REAL classi-
fication [19]. Although acc. to the WHO classification
it is a subtype of diffuse large B-cell lymphoma
(DLBCL), it is separately discussed as „mediastinal (thy-
mic) large B-cell lymphoma” with distinctive clinical, im-
munophenotypic and genetic features [20]. PMBL is a ra-
re lymphoma and it constitutes 0.9 to 3,7% of all non-
-Hodgkin lymphomas and 2,4 to 6.5% of large cell
lymphomas [10, 18, 21, 22, 35]. It affects young people
(median age 32 years), predominantly women [14, 16,
23-28] and presents on routine X-ray examination or CT
of the chest as an anterior mediastinal mass. PMBL inva-
des the adjacent anatomic sites by continuity, i.e. large
vessels, pleura, pericardium, trachea and the anterior
chest wall. The most frequent symptom is the superior
vena cava syndrome. Although a few symptomless cases
have been reported, the majority of patients complain
of pain or discomfort in the chest, dyspnea or cough [14,
22, 24, 27]. Some patients have B-symptoms at diagnosis.
The majority of patients are clinically in Ann Arbor sta-
ge I or II [29]. When the disease disseminates outside the
thorax, it usually involves the supraclavicular, cervical
and axillary lymph nodes. Only sporadically primary invo-
lvement of other organs (kidneys, adrenal glands, liver or
spleen) or retroperitonal lymph nodes, had been repor-
ted [3, 14, 24]. In comparison with other large B-cell
lymphomas, bone marrow involvement at diagnosis is
very seldom noted in PMBL [24]. Morphologically prima-
ry mediastinal large B-cell lymphoma displays signifi-
cant pleomorphism [3, 25] and some degree of sclerosis is
a common feature [20]. Patients with PMBL are treated
with combination chemotherapy followed by radiothe-
rapy [16, 30]. PMBL belongs to a group of highly mali-
gnant lymphomas with an aggressive, life threatening cli-
nical course. It is important to consider prognostic factors
at diagnosis. Clinical factors defined by International
Prognostic Index [31] are: age, Ann Arbor clinical stage
(I-IV), performance status (0-5), serum LDH level and
number of extranodal localisations. Evaluation of these
parameters enables to predict tumour growth rate, its
invasive potential, physical condition of the patient and
tolerance of intensive therapy. Poor prognosis is related
to large primary tumour (over 10 cm in diameter), lack of
remission after the first treatment or to cases of rapid re-
currence. Recurrences in other localizations, besides the
mediastinum, carry particularly adverse prognosis [18,
24, 32]. Studies from the 1980ies stressed the adverse
association of prognosis to the lack of response to treat-
ment. At present, with aggressive chemotherapy and ra-
diotherapy, complete remissions are more frequently
achieved, and in more than half of the treated patients 5-
-year survival is observed [18, 24, 30, 32]. Patients who do
not achieve remission or in whom it is very short and
followed by progression in the mediastinum or at distant
sites, usually die within the first two years. Besides the cli-
nical, histopathological prognostic factors have been se-
arched for and the tumour cell proliferation rate (Ki-67
index) has been one of the earliest and still considered
[33]. It is assumed that high values of this index (60-80%
and over) correlate with longer overall survival in tre-
ated patients [34, 35]. On the other hand in untreated pa-
tients (retrospective studies), high values of the prolifera-
tive index correlated with shorter survival. Gascoyne [36]
and Wilson et al. [37] suggest that lymphomas with a low
proliferation index show lower sensitivity to treatment
in comparison to those characterized by high prolifera-
tion index.
Expression of bcl-2 protein is an independent pro-
gnostic factor [31] and it does not correlate with the pre-
sence of the bcl-2 gene rearrangement. While the pre-
sence of t(14;18) accompanied by rearrangement of the
bcl-2 gene is observed in 15-25 % large cell lymphomas,
the bcl-2 protein expression is noted in about 25-50% of
these lymphomas [38]. It means that there must be some
other mechanism, besides the translocation, which wo-
uld be responsible for high expression of bcl-2 protein in
those lymphomas [36]. The bcl-2 protein is a biological
factor blocking apoptosis of the cells. Anti-apoptotic ef-
fect of the bcl-2 protein may alter the expected results
of chemo- or radiotherapy, therapeutic methods indu-
cing neoplastic cell death. Therefore, large B-cell lym-
phomas characterized by high expression of bcl-2 protein
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may manifest resistance to chemotherapy or radiotherapy,
resulting in lack of response to treatment.
Material and methods
C l i n i c a l  m a t e r i a l
The study was held on 51 patients with primary mediastinal lar-
ge B-cell lymphoma diagnosed in the Department of Pathology,
of The Maria Sk∏odowska-Curie Memorial Cancer Center and
Institute of Oncology in Warsaw in the years 1991-1998. The
group consisted of 28 women and 22 men aged from 17 to 67
years, (mean age 31,9 years). There was a predominance of wo-
men to men of 1.3: 1. Female patient age was 17-68 years (mean:
31.5), male patient age – 17 – 59 years (mean: 32.3). Clinical
diagnosis of mediastinal tumour was made in all 51 patients on
radiological and/or CT examination of the chest. The size of
the tumour was measured in centimeters, and when the diame-
ter exceeded 10 cm, it was considered to be large. The extent of
the disease was evaluated by physical examination, USG or CT
of the chest and the abdomen and, in 49 patients, by bone mar-
row biopsy. Patients were staged according to the Ann Arbor sys-
tem [39]. Serum lactate dehydrogenase (LDH) levels were deter-
mined in clinical laboratory with the maximum normal value
300 IU/l. Patients were treated with chemotherapy according
to the regimens: CHOP or MEVA (V-VIII courses) followed
by radiotherapy of the mediastinum (3600 – 4200 cGy/t). Results
of the treatment were expressed as complete remission (CR)
or no remission (NR) and as overall survival (OS) in months.
Complete remission was calculated from the moment of clinical
observation of disease regression following therapy till the mo-
ment of the last observation.
H i s t o p a t h o l o g i c a l  m a t e r i a l  a n d  m e t h o d s
Biopsies from mediastinal tumours were obtained by mediastino-
scopy or thoracotomy in 34 patients, from the lymph nodes
(bronchiothoracic, supraclavicular and cervical) in 10 patients,
from pleural and anterior chest infiltrations in 6 patients and
from the superior part of the tumour above the clavicula in 1 pa-
tient. Tissue samples were routinely processed and parafin sec-
tion were hematoxylin and eosin stained. Lymphomas were dia-
gnosed according to the REAL classification. Additional paraf-
fin sections were prepared for immunohistochemical studies.
A panel of antibodies was used: LCA, CK-MNF, CD 20, CD 3,
CD15, CD 30, kappa, lambda, MIB1 and bcl-2. However, not in
all the cases tissue samples were large enough to perform all
the immunocytochemical staining.
S t a t i s t i c  m e t h o d s
Only 50 patients were subject to the analysis (one patient was
excluded due to incomplete clinical data). Follow-up was conduc-
ted from January 1991 till March 2001, that is in time brackets
from 9 to 2 years. A two-year follow-up was the shortest and
concerned patients in whom the diagnosis was made in the years
1991-1998.
Statistic analysis included:
– Preparation of distribution of the analysed quantitative para-
meters (sex, stage, response to treatment, performance status
at last follow up) and presentation in groups of quantitive
parameters (age, tumour size, LDH level, MIB1 expression,
bcl-2 protein expression and overall survival) in numerical
values and as percentage of all the studied patients.
– Analysis of the effect of the above mentioned parameters on
duration of CR or NR – chi2 test.
– Analysis of survival
a) traditional method of Life Tables
b) comparison of curves – function of survival by log-rank test
Results and discussion
C l i n i c a l
Basic data and clinical results are presented in Table I.
In 21 patients the presence of the superior vena cava syn-
drome was the main clinical symptom. Most of the pa-
tients complained of pain or discomfort in the chest, co-
ugh and dyspnea. Recurrent infections of the upper respi-
ratory tract were manifestations of the tumour in 4
patients. Two patients had no complaints and the media-
stinal tumour was accidentally found on the radiological
examination of the chest. General symptoms were present
from the beginning of the disease in 23 patients. Aggres-
sive chemotherapy and radiotherapy of the mediastinum
were given. Complete remission was achieved in 21 pa-
tients with overall survival ranging from 36 to 99 months.
24 patients are alive, of whom 3 live with persisting dise-
ase. In the remaining 26 patients the treatment did not in-
duce regression and they died due to persistence of me-
diastinal tumour or progression to distant localisations.
One patient was lost to follow-up.
H i s t o p a t h o l o g i c a l
Morphological examination of tissue sections disclosed si-
gnificant pleomorphism of tumour cells. A range of mor-
phologic appearances facilitated allocation of cases to
five morphological groups. There were lymphomas com-
posed of germinal center cells (centroblasts and centro-
cytes), of „clear” cells, polymorphous large cells, some
contained cells resembling Reed-Sternberg and Hodg-
kin cells and some were small cell proliferations. Most
lymphomas displayed high or medium mitotic activity.
Various forms of sclerosis and/or hyalinisation of the
stroma were present in a majority of tumours. In all cases
immunohistochemical studies confirmed the diagnosis
of large B-cell lymphoma with fenotype: LCA+, CD20+
and lack of expression of cytokeratin, CD3, CD30 and
CD15. Only in 3 out of the 45 stained sections monoclo-
nal immunoglobulin light chain production was detec-
ted. On the basis of routinely stained HE sections, it
may be often impossible to make a correct diagnosis.
Not only due to morphological pleomorphism of lym-
phoma, mimicking other mediastinal tumours, but often
due to minute size of the sections, displaying frequently
the so-called „crush” artefact caused by tissue damage
during surgical excision.
In 45 out of 51 cases immunohistochemical reaction
with MIB1 antibody (Ki-67) was performed to evaluate
the proliferative activity of lymphoma cells. Depending on
the percentage of lymphoma cells expressing MIB1 anti-
gen, the cases were divided into groups:
80-100% cells expressing MIB1 – 20 cases
50 – 80% cells expressing MIB1 – 13 cases
<50% cells expressing MIB1 – 12 cases
Bcl-2 protein expression was also immunohistochemical-
ly tested in 45 cases. Only in 28 cases cytoplasmic labelling
was noted and these were subdivided into 2 groups depen-
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ding on the percentage of cells displaying bcl-2 protein
expression;
>50% cells – 22 cases
< or = 30% cells – 6 cases
In the 17 remaining cases lymphoma cells did not display
the expression of bcl-2 protein.
S t a t i s t i c  r e s u l t s
Distribution of the analyzed clinical and histopathological
parameters is presented in Table II.
In an analysis of the effect of several parameters on
the results of treatment, that is obtaining either complete
remission (CR) or no remission (NR), it was disclosed
with the chi2 test, that the tumour size had a statistical si-
gnificant effect, as shown in Table III.
Table I. Basic clinical data and results in 51 patients with PMBL
No Age Sex Tumour size Ann Arbor LDH CR/NR OS Deaths
(cm) clinical stage (IU/l) (mth) (mth)
1 52 M >10 IA - NR 13 +
2 46 F >10 IA 239 CR87 99
3 30 F >10 IB - - 1 +
4 36 F - - - - - -
5 25 F >10 IVB - NR 7 +
6 45 M >10 IB - NR 15 +
7 43 F >10 IIA 686 NR 24 +
8 33 F <10 IA - NR 11 +
9 35 M <10 IA 345 CR-82 88
10 17 M <10 IA 319 CR-68 74
11 19 F >10 IA 480 CR-68 74
12 47 F >10 IIB 1532 NR 24 +
13 17 F - - - NR 10 +
14 17 F >10 IIB 1003 NR 12 +
15 17 F >10 IA 1074 NR 2 +
16 48 M >10 IA - CR-74 80
17 32 M <10 IA 227 NR 8 +
18 31 F >10 IA 1010 NR 15 +
19 19 F >10 IIB 2107 NR 1 +
20 18 F 10 IA 1360 CR-52 60
21 22 M - - - NR 4 +
22 59 M >10 IVB 355 NR 10 +
23 19 F >10 IIIA 1092 NR 37 +
24 41 F >10 IA 525 NR 12 +
25 39 M <10 IIB 651 CR-46 52
26 22 M >10 IIIB 644 NR 8 +
27 31 F - IA - CR-45 51
28 40 F <10 IA 260 CR-48 53
29 33 F >10 IB 218 CR-50 56
30 28 M >10 IB 1829 CR-32 39
31 17 F >10 IIEB 1051 NR 12 +
32 28 M - - - CR-? 43
33 31 F <10 IIB 884 NR 13 +
34 19 F >10 IIB 408 CR-34 42
35 18 F >10 IIA 85 CR-28 36
36 23 M >10 IB 302 NR 9 +
37 21 M >10 IA 417 CR-25 40
38 25 M >10 IIB 1919 NR 21 +
39 20 M <10 IA 815 CR-40 45
40 43 M <10 IB 544 CR-38 45
41 20 M <10 IA 290 CR-38 46
42 18 M >10 IVB 3547 NR 18 +
43 38 F <10 IB 250 CR-21 36
44 32 F >10 IIA 1160 CR-30 36
45 50 F >10 IIB 529 NR 29
46 68 F <10 IA 1915 NR 12 +
47 34 F >10 IB 956 NR 8 +
48 29 M >10 IB 850 CR-? 52
49 27 F <10 IA - NR 24
50 40 F >10 IA 681 NR 24
51 25 M >10 IIB 705 NR 1 +
LDH – serum lactate dehydrogenase level
CR – complete remission (in months)
NR – no remission (in months)
OS – overall survival (in months)
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Analysis of other clinical and histopathological para-
meters did not show any statistically significant differen-
ces between the studied groups. In an analysis of overall
survival (OS) calculated with the traditional method of Li-
fe Tables, for the entire group of patients, the percentage
of 2 year survival was 54%, at standard error 7.0, and 5
year survival (for patients diagnosed in years 1991-1995)
– 27.3% with standard error 9.5. In analysis of the ratio of
2 year survival depending on tumour size, a tendency for
shorter survival was noted in the group with tumour dia-
meter over 10 cm (Table IV).
In an analysis employing the traditional method of
Life Tables in relation to other clinical and histological pa-
rameters, no statistically significant differences were fo-
und regarding 2 year survival. Two year survival curves we-
re also plotted using the Kaplan and Meier method and
survival curves were compared between the categories
of the analyzed parameters with the use of log-rank test
(Table V).
Discussion
The above discussed group of 51 PMBL is not very nume-
rous, but this unique lymphoma is rare. The largest study
published so far was based on 141 cases [24], while the
few other reports [3, 16, 23-25, 28, 29, 40] presented some
10 to 20 cases. Altogether over 300 cases of PMBL have
been reported. This study further confirms several of the
Table II. Distribution of the analyzed clinical
and histopathological parameters





up to 39 years 37 72
40 years and more 14 28
Tumour size 
<10 cm 14 30
>10 cm 32 70
no data 5
Ann Arbor clinical stage
I i II 42 89
III i IV 5 11
no data 4
LDH
to 300 IU/l 6 15
301 – 1000 IU/l 20 51
above 1000 IU/l 13 34
no data 12
MIB 1
to 50% 18 40




1-30 % 6 13
above 30% 22 49
no data 7
Table III. Response to treatment of patients with primary mediastinal lymphoma depending on tumour size
Response
Tumour size Complete remission - CR No remission – NR Total
Number of patients % Number of patients % Number  of patients %
<10 cm 9 64.3 5 35.7 14 100.0
>10 cm 10 32.3 21 67.7 32 100.0
Total 19 42.2 26 57.8 45 100.0
Table IV. Overall 2 year survival of patients with primary mediastinal lymphoma depending on tumour size
Tumour size
Survival in years <10 cm (n=14) >10 cm (n=32)
Survival rate % Standard error Survival rate % Standard error
1 year 85.7 9.4 71.9 7.9
2 years 71.4 12.1 46.9 8.8
n – number of patients p=0.065
Table V. Comparison of survival curves between the categories of analyzed parameters with log-rank test
Parameter Probablility Interpretation of the results
p
sex 0. 462 non significant survival curves
age 0. 896 non significant survival curves
tumour size 0. 0436 significantly shorter survival of patients with tumours >10 cm
Ann Arbor clinical stage 0. 110 tendency for shorter survival of patients with stage III and IV
LDH level 0. 166 tendency for shorter survival of patients with higher LDH level
MIB1 (<50% and >50%) 0. 807 non significant survival curves
MIB1 (<80% and >80%) 0. 834 non significant survival curves
bcl-2 (0%, 1-30% and >30%) 0. 168 tendency for shorter survival of patients with bcl-2 = 0%
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characteristic features of PMBL. Clinically there was
a predominance of women to men (1.3: 1), and 71.4%
were young women (aged 17-39 years), which is conside-
red very characteristic for this entity [3, 14, 16, 24, 27].
The majority of our 42 out of 51 patients (82.4%) presen-
ted in Ann Arbor stage I or II, and CR was achived in this
group in 87.9% of patients. On the contrary, no response
to treatment (NR) was observed in patients in Ann Arbor
stage III and IV; they all died. Cazals et al. [24] conside-
red their patients in Ann Arbor stage I and II (68% of pa-
tients) as a good prognosis group, in comparison to other
diffuse large B-cell lymphomas at the same (early) clinical
stage of involvement. Bone marrow involvement in the
presented study was found only in 2 patients (4.2%). Ca-
zals et al. [24] noted that bone marrow involvement in
their 2% cases was significantly less frequent than in
DLBCL. Other authors [3, 23, 41] stressed the lack of
bone marrow involvement. General symptoms are un-
common in PMBL, but when present, they indicate poor
prognosis [40]. In our material they were present in 23
(45.1%) of patients. In 14 of those no remission was
achieved following the treatment and they died, with ove-
rall survival from 1 to 24 months. Among other clinical fe-
atures of prognostic significance are: the size of primary
tumour and LDH level at diagnosis. In 32 (69.6%) of our
patients mediastinal tumour was over 10 cm in diameter
and CR was obtained only in 10 of them (32.3%). The re-
maining patients had no remission and all but one died.
Of 14 cases of tumours below 10 cm in diameter CR was
achieved in 9 (Table III). Statistical analysis showed corre-
lation between the size of the primary tumour and the
duration of overall survival (p=0.0436) with significantly
shorter survival of patients with tumour size >10cm. Ja-
cobson et al. [18] and others [3, 27, 31] reported similar
findings stressing that tumour size was an important pro-
gnostic factor correlating with the achievement of CR
following the treatment. Regarding serum LDH level, in
33 of our patients it was elevated and among those in 13
(33.3%) highly elevated – 10 of them died with NR.
Among 6 patients with normal LDH level CR was achie-
ved in 5. Statistical analysis of this parameter showed
a tendency for shorter survival of patients with an elevated
LDH (p>0.166). The opinions in literature regarding the
prognostic significance of LDH are different. Jacobson et
al. [16] did not observe any differences in survival betwe-
en patients with high and normal LDH levels. Others [5]
showed that although high LDH levels are more frequent
in PMBL (76%) than in other large B cell lymphomas
(51%), no correlation was found between LDH levels
and effects of treatment in PMBL. However our material
is too small for valid statistic analysis due to PMBL rarity.
On histopathological examination of PMBLs, the
cells may appear uniform or display significant pleomor-
phism resembling a variety of other neoplasms that may
be also present in the mediastinum. A frequently descri-
bed „clear cell pattern” of PMBL [15] may be errone-
ously interpreted as mediastinal seminoma or metastatic
renal cell carcinoma. Many authors called attention to
primary misdiagnoses of Hodgkin lymphoma, thymic car-
cinoma or even sarcoma in their cases of PMBL [3, 14,
41]. Immunohistochemical staining with CD20 has been
established as absolutely indispensible in the diagnosis
of mediastinal tumours. When tissue samples are very
small and with crush artifact resembling small cell lung
cancer and routinely stained HE sections are very difficult
to interpret, immunocytochemical staining with cytokera-
tin and CD 20 will differentiate between carcinoma and
B-cell lymphoma. Due to aggressive tumour growth and
a tendency to infiltrate the adjacent anatomic sites it is ve-
ry important to establish the diagnosis without any de-
lay and implement the treatment. Therefore, the state-
ment of Lamarre and collegues [16] that: „The single
most important factor in establishing the correct diagno-
sis is a high index of suspicion on the part of the patholo-
gist” is not outdated.
At present oncological diagnostics are frequently ba-
sed on cytology and one must be aware that it is not suffi-
cient in lymphomas. In 2 of our cases, the first diagnostic
material was a FNAB of mediastinal tumour where on the
basis of cytological appearance squamous cell carcino-
ma was diagnosed in one case and an undifferentiated
carcinoma in the other. Correct diagnosis was not establi-
shed until later, when a tumour biopsy was taken and im-
munohistochemical studies enabled the diagnosis of large
B-cell lymphoma. Cytopathological reports [42] of the
last few years warn that FNAB of mediastinal tumours is
of diagnostic value only when supplemented by immu-
nohistochemical studies. Slagel et al. [43] mentioned the
possibility of incorrect diagnosis in cytological material of
various mediastinal tumours which contain a spindle cell
component. Yu [44] presents a case of thymic epithelium
entrapped by PMBL, which happened to be the main cy-
tological component causing misdiagnosis of thymoma. It
is apparent that in case of mediastinal tumours, histopa-
thological evaluation of tissue sections supplemented by
immunohistochemical studies is the most sensitive dia-
gnostic procedure. Rarely, a supraclavicular or cervical
lymph node is the primary diagnostic material. However
with the knowledge of the characteristic clinical presenta-
tion of this mediastinal tumour and with the aid of immu-
nohistochemical staining the pathologist will be able to
make a correct diagnosis of PMBL.
Searching for morphological prognostic factors, the
cell proliferation index was evaluated in 51 cases. Slightly
better effects of treatment were observed in cases
with MIB1>50% (out of 21 patients with CR, in 11
MIB1>50%, and in 8 it was between 80-100%). This ob-
servation would be in agreement with data from literatu-
re [24, 25, 34, 35, 37].
Evaluation of bcl-2 protein expression in lymphoma
cells is also a morphological prognostic factor. High
expression usually correlates with diminished sensitivity to
treatment, while lack or low expression is associated with
great sensitivity to treatment. In our study, high and me-
dium bcl-2 protein expression was found in 22 cases – 12
of them did not achieve remission, 10 died subsequen-
tly. In 23 cases bcl-2 protein was not expressed or expres-
sed in less than 30% of cells. Only 9 patients of this group
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achieved CR following the treatment. Our observation
differs from that of other authors, but it may require fur-
ther studies on a larger material to clarify this point.
Regarding histogenesis, PMBL derives from thymic
B-cells [14, 20]. Its immunophenotype is identical with
that of these cells (CD19 and CD20+, CD21, CD5 and
CD10-). The results of the above presented study as well
as those from literature indicate that cytoplasmic or sur-
face immunoglobulin expression is seldom found [14, 20],
although genetic studies show rearrangement of the heavy
and light chain immunoglobulin genes [20]. Molecular
studies on 3 translocations common in B-cell non-Hodg-
kin lymphomas indicate essential differences between
PMBLs and other DLBCLs [45, 46]. Two of these chro-
mosomal abnormalities, t(14;18) involving bcl-2 gene and
t(8;14) involving c-myc gene, show strong association with
histological subtypes of lymphomas. The first one is com-
mon in follicular lymphomas, and in about 30% of the
DLBCLs, while the second one appears in Burkitt's and
Burkitt type lymphomas, in AIDS-associated lymphomas
and in about 20% of DLBCL [45]. The bcl-6 gene is
expressed in non-Hodgkin lymphomas originating from
germinal center B lymphocytes and it is associated with
chromosomal abnormalities frequently found in DLBCLs
[46]. The studies of Scarpa et al. [45] on a series of 6 and
later Tsang et al. [46] on 16 PMBLs showed a variety of
molecular changes; however, bcl-2 gene rearrangement
had not been detected in any of the 2 sets of cases. Only
in one of the 16 PMBL cases [46] the bcl-6 gene rear-
rangement was found. The c-myc abnormalities were de-
tected in 3 plus 3 cases from each study. Copie-Bergman
has recently reported [47] the presence of MAL gene in 8
out of 12 cases of PMBL and MAL protein expression in
7 out 12. Just to compare, 8 control cases of DLBCL we-
re analyzed and only in 2 low levels of MAL m-RNA we-
re detected but with no protein expression. Genetic ana-
lysis of 26 PMBL cases [48] disclosed several characteristic
abnormalities, mainly gains concerning chromosomes 2,
12, X and 9 and amplification of the REL gene. Among
these, chromosome 9 overrepresentation was considered
quite unique since it does not appear in any other non-
-Hodgkin lymphoma.
All the new findings mentioned above indicate that
PMBLs display molecular and genetic changes that differ
from those characteristic for other DLBCLs. Thus it is ful-
ly justified to define primary mediastinal large B-cell lym-
phoma as an entity with distinct clinicopathological and
biological features.
Conclusions
1. In the analyzed group of 51 cases of PMBL a great
variety of morphological pattern was noted. Some lym-
phomas resembled other neoplasms that may be lo-
calized in the mediastinum.
2. In histopathological evaluation of mediastinal tumours
it is indispensible to do a panel of immunohistochemi-
cal stains enabling differential diagnosis between epi-
thelial tumours, Hodgkin lymphoma and T or B lym-
phomas. It is equally important to be familiar with cli-
nical presentation of the tumour in each case.
3. Statistic analysis showed that tumour size had a statisti-
cally significant effect on overall survival. Other analy-
zed parameters only displayed tendency for correla-
tion.
Doc. dr hab. med. Renata K. Maryniak
Laboratory of Pathomorphology
Institute of Haematology
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